CClinicalTrials.gg
RecruitingNCT06388460Updated May 5, 2026

Asthma Link Effectiveness Trial

An interventional study of Asthma Link and Enhanced Usual Care in Childhood Asthma, sponsored by University of Massachusetts, Worcester. Recruiting at 1 site in United States. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by University of Massachusetts, Worcester · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
5 Years to 14 Years
Sex
All
01

Study summary

The goal of this cluster Randomized Control Trial is to determine the effectiveness of Asthma Link, a school supervised asthma therapy program, compared with an educational asthma workbook, in improving asthma symptoms for children with poorly controlled asthma aged 5-14.

Read the detailed description

Asthma is an extremely common chronic disease in childhood with significant morbidity. The majority of asthma morbidity in children is due to medication non-adherence, and both morbidity and medication non-adherence disproportionately impact minoritized children. School-supervised asthma therapy ensures that children receive their preventive asthma medication daily at school and has shown efficacy in improving medication adherence and asthma health outcomes, particularly in low-income and racial/ethnic minority children. However, this strategy has not been widely adopted in practice to produce meaningful public health impact. To address this gap, the study team developed a new model, Asthma Link, which partners pediatric practices, schools, and families to deliver school-supervised asthma therapy. This intervention leverages established infrastructure and requires minimal resources to operate, enhancing sustainability in a real-world setting. The pilot trial of Asthma Link showed improved asthma symptoms when compared to an enhanced usual care condition, particularly among low-income, Black and Latino children, and demonstrated trial feasibility. Moreover, the research team has rigorously adapted this intervention for real-world use using input from diverse, multi-level community stakeholders.

This 14 site cluster randomized controlled trial will determine the effectiveness of Asthma Link versus an enhanced usual care condition in improving asthma health outcomes in school-aged children with poorly controlled asthma.

The investigators central hypothesis is that children in Asthma Link will have higher Asthma Control Test scores at 6 months compared with children in enhanced usual care; with maintained improvements at 12 months. The secondary hypothesis is that children in Asthma Link will have higher inhaled corticosteroid adherence and quality of life scores, and lower rates of asthma exacerbations, school absences and parental lost workdays compared with children in the enhanced usual care condition.

02

Conditions studied

  • Childhood Asthma

Keywords

  • asthma
  • childhood asthma
  • medication adherence
  • school-supervised asthma therapy
  • real-world
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's planned enrollment of 350 is above the median of 83 across 2,752 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

University of Massachusetts, Worcester is the lead sponsor of 288 studies on the registry; 54 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

STUDY INCLUSION/EXCLUSION CRITERIA:

Child Inclusion Criteria:

  • Meet the eligibility criteria for Asthma Link (as described below)
  • Enrolled in Asthma Link (if randomized to the Asthma Link Condition)
  • Able and willing to provide informed assent

Child Exclusion Criteria:

  • Unable or unwilling to provide informed assent
  • Developmental delay that would prevent study participation.

Parent Inclusion Criteria:

  • Parent/guardian to patient
  • 18 years or older
  • Able to understand and communicate in English or Spanish
  • Able and willing to provide informed consent.

Child eligibility for children enrolled in Asthma Link:

  • children aged 5-14 years (enrolled in grade K-8)
  • prescribed daily inhaled corticosteroid (ICS) for asthma
  • Asthma Control Test (ACT) score ≤19 OR 1 or more of ANY of following in the past 1 year: course of oral steroids, hospitalization, Emergency Department visit, sick visit for asthma
  • parent/child report of poor ICS adherence on adherence checklist- i.e. child or parent says "Yes" when provider asks if they have difficulty remembering to take their medication or if they regularly take medication holidays or breaks
  • able and willing to assent
  • parental permission
  • English or Spanish speaking
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Asthma Link

    Practices in the Asthma Link condition will receive brief training on how to identify, refer and arrange for children with poorly controlled asthma to receive school-supervised therapy with the child's school health staff. Participants will receive an educational asthma workbook.

    Other: Asthma Link

  • Active comparator
    Enhanced Usual Care

    Practices in the Enhanced Usual Care condition will receive brief training on how to identify and refer the same group of children with poorly controlled asthma and these children will receive an educational asthma workbook.

    Other: Enhanced Usual Care

Interventions

  • OtherAsthma Link

    Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook

  • OtherEnhanced Usual Care

    Providers enroll patients to receive an asthma educational workbook

06

What researchers measure

Primary outcomes

  1. Improving Asthma Symptoms

    Asthma Control Test to measure child's asthma control on a scale of 0-25. A score of 19 or less is considered poorly controlled asthma.

    Time frame: Baseline, 6 months, 12 months

Secondary outcomes

  1. Improving Medication Adherence

    Survey to measure medication adherence

    Time frame: Baseline, 6 months, 12 months

  2. Improving Healthcare Utilization

    Survey questions to measure # of emergency room visits, # of hospital admissions, # of oral steroid courses due to asthma

    Time frame: Baseline, 6 months, 12 months

  3. Reducing Parental Lost Workdays

    Survey to measure the number of days a parent has missed work

    Time frame: Baseline, 6 months, 12 months

  4. Reducing School Absences

    Survey to measure the number of days a child has missed school

    Time frame: Baseline, 6 months, 12 months

  5. Improving Quality of Life

    Survey to measure the quality of life of the child and parent

    Time frame: Baseline, 6 months, 12 months

07

Study locations

1 of 1 sites recruiting
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06388460
Lead sponsor
University of Massachusetts, Worcester
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Michelle Trivedi (Associate Professor, University of Massachusetts, Worcester) — Principal investigator
First posted
Apr 29, 2024
Start date
Apr 4, 2024
Primary completion
Jan 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
May 5, 2026

Study contacts

Michelle Trivedi, MD
Contact
Michelle.Trivedi3@umassmed.edu
7744418086
Michelle Spano, MA
Contact
michelle.spano@umassmed.edu
17746966875
Michelle Trivedi, MD
principal investigator · UMass Chan Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion